| Autor: |
Chybicka A; Katedra i Klinika Hematologii i Chorób Rozrostowych Dzieci, 50-345 Wroclaw, Bujwida 44, Poland., Bogusławska-Jaworska J, Rosińska B, Wecławek-Tompol J, Armata J, Balcerska A, Balwierz W, Bubala H, Drabko K, Eliasinska A, Kedziora M, Sońta-Jakimczyk D, Sopylo B, Kołecki P, Kowalczyk J, Matysiak M, Rokicka-Milewska R, Stefaniak MJ, Stańczak E, Stencel D, Wysocki M, Płoszyńska A |
| Jazyk: |
polština |
| Zdroj: |
Medycyna wieku rozwojowego [Med Wieku Rozwoj] 2000; Vol. 4 (1 Suppl 2), pp. 121-9. |
| Abstrakt: |
A total number of 608 cycles of G-CSF and/or GM-CSF was applied in 280 patients aged from 6 months to 20 years during neutropaenia associated with chemotherapy of children's neoplasms (NHL-124, NBL-42, RMS-36, Nephroblastoma-18, Osteosarcoma-17, Ewing's Sarcoma-14, Hepatoblastoma-6, Neurofibrosarcoma-6, PNET-5, Medulloblastoma-3, Fibrohistiocytoma-3, Angiosarcoma-2, other - 4). G-CSF - Neupogen (Filgastrim, Hoffman La Roche - 492 cycles) and GM-CSF - Leucomax (Molgramostim, Shering Plough - 116 cycles) were administered 5 mg/kg/day s.c. Forty one children with malignancies (NHL -21 cases, solid tumours -17) treated before cytokines were in use served as a control group. Our study demonstrated that G-CSF and GM-CSF therapy, gives a shorter period of neutropaenia, reduction of the number of febrile days, decreased frequency of infection and shortened its duration. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
